header logo image


Page 264«..1020..263264265266..270280..»

Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung…

January 31st, 2021 2:46 am

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients with advanced non-small cell lung cancer (NSCLC), profiling remains suboptimal due to continued reliance on invasive tissue biopsies for testing. A new study published in JCO Precision Oncology confirms previously reported data showing that the Guardant360 liquid biopsy is not only concordant to tissue genotyping, but detects significantly more informative alterations when used prior to tissue testing, and achieves similar treatment response rates and progression-free survival in patients with NSCLC. Publication link here.

The prospective study1 (n=186) compares comprehensive genomic profiling using the Guardant360 liquid biopsy versus standard-of-care tissue genotyping for first-line treatment decisions in advanced NSCLC. Patients with advanced NSCLC received targeted therapies based on the actionable biomarkers identified. Compared to tissue biopsy genotyping at time of diagnoses, the Guardant360 liquid biopsy was not only concordant with tissue biopsy but detected 23.6 percent more informative mutations when used first and before tissue biopsy.

The study adds to the growing body of evidence2-4 demonstrating that using a blood-first approach using the Guardant360 test for genomic biomarker detection can identify more actionable biomarkers than a tissue-first approach. Importantly, objective response rates and progression-free survival in biomarker-positive patients receiving targeted therapy was similar to previously reported registrational trials.

Despite the ever-growing availability of life-changing targeted drugs for treating patients with advanced lung cancer, many continue to be treated with chemotherapy or immunotherapy because first-line treatments are made without conducting comprehensive genotyping first, said the Principal Investigator of this study Dr. Rafael Rossell, Chief Medical Officer and President of the Dr. Rosell Oncology Institute. This publication outlines further evidence that the Guardant Health liquid biopsy is very effective in uncovering actionable genomic alterations, overcomes the challenges of tissue biopsies, and helps clinicians more easily customize treatments to improve the prognosis and survival of their patients.

Numerous clinical studies show that patients receiving targeted or personalized treatments have improved progression-free survival and higher overall response rates compared to chemotherapy or immunotherapy.5-11 Various factors contribute to clinical adoption of personalized medicine lagging behind recommended medical guidelines, including insufficient tissue for biopsy, which is the case for as many as 30 percent of solid cancer patients.12-14

Once again, the data show that our blood-first approach using our Guardant360 liquid biopsy has the advantage of increasing the number of patients receiving potentially life-changing targeted treatments without compromising treatment efficacy, said Helmy Eltoukhy, Guardant Health CEO. Sadly, research indicates that approximately 80 percent of advanced lung cancer patients do not receive comprehensive genotyping before starting treatment. I hope that with the recent FDA approval of our Guardant360 CDx liquid biopsy test, more clinicians will feel confident making the shift to liquid biopsies so we can reverse the serious trend of undergenotyping that exists today.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Healths liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Healths financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operation and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2019, in its Quarterly Reports on Form 10-Q for the periods ended March 31, 2020, June 30, 2020, and September 30, 2020, respectively, and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Healths views as of any date subsequent to the date of this press release.

References

More:
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung...

Read More...

Nutraceutical Products Market Size To Reach USD 461.70 Bn By 2027 | Growing Demand for Fortified Food Owing to the Increasing Health Consciousness…

January 31st, 2021 2:46 am

New York, Jan. 28, 2021 (GLOBE NEWSWIRE) -- The nutraceutical products market was valued at USD 270.96 Billion in the year 2019 and has been projected to rise at a CAGR of 7.1% from 2020 to 2027. Nutraceutical products are mainly a part of food that delivers several nutritional values to the diet. It is also considered as functional foods, containing pharmaceutical-grade and standardized nutrients. These supplements are the source of dietary supplements and work towards preventing diseases. People globally are becoming more inclined towards diverse food and beverage types, having added various nutritional supplements; thus, nutraceutical products are gaining traction.

Globally, various nutraceutical products are gaining immense popularity, becoming a part of the daily diet of consumers. The rising prevalence of various lifestyle diseases and the growing number of people taking numerous preventive healthcare measures are stimulating demand in the industry. Increasing utilization of a wide range of functional food and beverages by the young population is further augmenting the markets growth over the estimated era. High technological progress in the area of nutraceutical products is also contributing to the industrys development. A trend of personalized medicine is likely to trigger demand for nutraceutical products.Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/2421

The market for nutraceutical products is primarily fueled by factors such as rising awareness about health among the aging population, increasing costs of health care, diet-disease links, and fast advancements in nutrition and food technology. Currently, various health concerns, including cardiovascular disease, cholesterol reduction, and osteoporosis, are attractive targets for a range of nutraceutical products, followed by high blood pressure, menopause-related ailments, child development, diabetes, GI disorders, and lactose intolerance.

Further key findings from the report suggest

Buy Your Copy Now (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/2421

Segments covered in the report:

This report forecasts revenue growth at global, regional & country levels, and provides an analysis of market trends in each segment and sub-segment from 2017 to 2027. For the purpose of this study, Reports and Data has segmented the nutraceutical products market on the basis of source, product, distribution channel, and region:

Source Outlook (Revenue, USD Million; 2017-2027)

Product Outlook (Revenue, USD Million; 2017-2027)

Distribution Channel Outlook (Revenue, USD Million; 2017-2027)

Click on the link to read key highlights of the report and look at projected trends for years to come: https://www.reportsanddata.com/report-detail/nutraceutical-products-market

Regional Outlook (Revenue, USD Million; 2017-2027)

Take a Look at our Related Reports:

Personalized Nutrition Market Size, Share & Analysis, By Type (Nutrition, Active Measurement Tools, Services), By Application (General Health, Medical, Sports), And By Channel (Direct-to-Consumer, Wellness & Fitness Centers, Hospitals & Clinics), Forecasts To 2027

Digestive Health Products Market Size, Share & Analysis, By Ingredient (Prebiotics, Probiotics, Digestive Enzymes), By Product (Non-Alcoholic Beverages, Bakery & Cereals, Dairy), By Distribution Channel (Modern Trade, Convenience Stores, And Online Retailers) And Region, Forecast To 2027

Resistant Maltodextrin Market Size, Growth Trends & Analysis By Type (Corn-Based, Wheat-Based, Potato-Based, Others), By Application (Beverages, Bakery & Confectionery, Dairy Products, Nutraceuticals, Others), By Region, Forecast To 2027

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports And Data | Web: http://www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

LinkedIn | Twitter | Blogs

Read Full Press Release@ https://www.reportsanddata.com/press-release/global-nutraceutical-products-market

See more here:
Nutraceutical Products Market Size To Reach USD 461.70 Bn By 2027 | Growing Demand for Fortified Food Owing to the Increasing Health Consciousness...

Read More...

FDA Clearance for Hepatica, Perspectum’s Surgical Decision Support Tool for Liver Cancer – Business Wire

January 31st, 2021 2:46 am

DALLAS--(BUSINESS WIRE)--Perspectum announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Hepatica, a precision oncology decision support tool for liver cancer.

Each year, around 200,000 Americans are diagnosed with primary or secondary liver cancer, with surgery as one of the key treatment options. The success of surgery relies on the volume and health of the remaining liver, which is impacted by any underlying chronic liver disease (CLD). Fatty liver disease, chronic viral hepatitis B and C as well as alcoholic liver disease affect nearly 100 million Americans, with prevalence increasing. Accurate pre-surgical assessment of liver health is therefore urgently needed to improve the outcomes for patients.

Hepatica uses non-invasive quantitative multiparametric MRI to provide a liver health assessment based on AI-driven liver segmentation together with proprietary biomarkers for hepatic fibro-inflammation and fat. Using AI to delineate the liver and calculate regional volumes saves over 20 minutes of pre-operative radiology time per case.

Initial results from UK-based study on 143 surgical candidates showed that by combining estimated future liver remnant with an assessment of underlying fibro-inflammation, Hepatica could effectively identify patients at risk of poor outcomes from surgery and a longer stay in hospital. This information enables tumour boards and multidisciplinary teams to make more informed pre-operative decisions to improve post-operative outcomes for patients, translating to cost-savings in associated care.

Mr Myrddin Rees, Consultant General and Hepatobiliary Surgeon at HHFT commented, As a hepato-biliary surgeon with over 30 years of experience operating on the liver I am thrilled that Hepatica is now cleared for clinical use. The missing element in all our current diagnostic, non-invasive imaging is an accurate assessment of the quality of the liver parenchyma. Hepatica provides the surgeon with a measure of liver well-being that allows us to push the boundaries on the one hand whilst avoiding the removal of inappropriate liver volume on the other. This work is a significant advance in our quest to treat more patients with liver disease whilst armed with the knowledge of what can be achieved safely.

Hepatica seamlessly integrates into the clinical workflow and provides a simple, patient-friendly report via a cloud-based service.

Hepatica is an advanced oncology tool that provides objective information to guide personalized clinical management, said Professor Claude Sirlin, Professor of Radiology at University of California, San Diego. It is an excellent application of smart imaging and Artificial Intelligence in medicine, and I look forward to seeing how it can be used in a variety of indications to improve clinical care.

Notes to Editors

About Hepatica

Hepatica is a precision oncology tool for clinical and surgical decision support tool based on non-invasive quantitative multiparametric MRI. It identifies high risk patients and enables more informed preoperative decision making, therefore improving post-operative outcomes. Hepatica has demonstrated utility in identifying patients at risk of poor outcomes, with the potential to inform surgical planning and realize significant cost savings through lowering the post-surgical complication rate, associated in-patient hospital stay and reducing time required from radiologists.

About Perspectum

Perspectum delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver disease, diabetes and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers and technologists, Perspectum offers a way to manage complex health problems at scale. For more information, visit perspectum.com.

Read the rest here:
FDA Clearance for Hepatica, Perspectum's Surgical Decision Support Tool for Liver Cancer - Business Wire

Read More...

Biotechnology research and policy expert joins Thunderbird School of Global Management and Sandra Day O’Connor College of Law at ASU through World…

January 31st, 2021 2:45 am

Doxzen's two-year joint appointment is part of a cutting-edge collaboration between WEF's Centre for the Fourth Industrial Revolution (C4IR) in San Francisco and the two schools based on ASU's Downtown Phoenix campus. As a Hoffmann Fellow, Doxzen will lead transnational projects that explore and tackle global policy and governance challenges in healthcare driven by emerging biotechnologies such as gene editing and synthetic biology.

"We're thrilled to have Kevin in this high-impact role, which gives us an opportunity to re-imagine precision medicine by leveraging new biotech in developing countries in spite of low-resource challenges," said Thunderbird's Director General and Dean, Sanjeev Khagram.

"Kevin's experience and expertise in genome-editing research and policy position him to be a difference-maker on a global scale through this prestigious fellowship. Working with faculty, administrators, and professionals spanning the worldwide networks of Thunderbird, ASU Law, and WEF, he will advance scholarship and experimentation in an international community to create resilient, robust governance frameworks that guide emerging biotechnologies such as CRISPR for the benefit of humanity," said Khagram.

"ASU Law, through its Center for Law, Science and Innovation, and Thunderbird have a long history of working with WEF at the intersection of law, governance and emerging technologies," said ASU Law's Associate Dean for International Engagement Di Bowman. "Partnering with WEF's C4IR to host esteemed Hoffmann Fellows represents a new and exciting chapter in our collaboration and we are delighted to welcome Kevin as our first fellow."

"Global healthcare challenges depend on global solutions that harness scientific and technological advances from diverse sectors and disciplines," said Genya Dana, Head of Healthcare Transformation at the World Economic Forum. "We are excited to welcome Kevin to the Forum's C4IR to help us lead efforts to ensure that emerging biotechnologies support equitable and ethical health and healthcare advances. We look forward to this collaboration withleading-edge partners at ASU to design and pilot new business models, policies and collaborative approaches to supporting the translation of cutting-edge science into treating and even curing rare diseases, blood disorders, and cancers."

"The Coronavirus Pandemic and the new era of biotechnology associated with the Fourth Industrial Revolution that COVID-19 is accelerating highlight the vital importance of the work Kevin has already started," said Professor Landry Sign, search committee chair and Senior Director of Thunderbird's Fourth Industrial Revolution and Globalization 4.0 Center. "And as a Hoffmann Fellow at ASU, he'll continue tapping into a global spectrum of experts to advance both practice and policy in next-generation precision medicine, producing new knowledge and high-tech healthcare tools with real-world impact."

About Thunderbird School of Global ManagementThunderbird School of Global Management is a unit of the Arizona State University Enterprise. For 75 years, Thunderbird has been the vanguard of global management and leadership education, creating inclusive and sustainable prosperity worldwide by educating future-ready global leaders capable of tackling the world's greatest challenges. Thunderbird's Master of Global Management was ranked #1 in the world for 2019 by the Wall Street Journal/Times Higher Education. ASU is ranked No. 1 "Most Innovative School" in the nation by U.S. News & World Report for six years in succession. Thunderbird Executive Education has been ranked in the top 10 internationally for decades.

About the Sandra Day O'Connor College of LawThe Sandra Day O'Connor College of Law at Arizona State University is one of the nation's preeminent law schools, focused on offering students a personalized legal education. Ranked No. 1 in Arizona since 2010 and No. 24 nationally by U.S. News & World Report, ASU Law offers students the opportunity to tailor their education, to match externships to their interests and career services resources to help land their ideal jobs. Additionally, ASU Law's LEED Gold certified building in downtown Phoenix is steps away from the legal, political and economic heart of Arizona. For more information, visit law.asu.edu.

About ASUArizona State University has developed a new model for the American Research University, creating an institution that is committed to access, excellence, and impact. ASU measures itself by those it includes, not by those it excludes. As the prototype for a New American University, ASU pursues research that contributes to the public good, and ASU assumes major responsibility for the economic, social, and cultural vitality of the communities that surround it.

CONTACT:Jonathan Ward Thunderbird Media Relations[emailprotected]+1 480.490.9773Download Media

SOURCE Thunderbird School of Global Management

https://thunderbird.asu.edu/

More here:
Biotechnology research and policy expert joins Thunderbird School of Global Management and Sandra Day O'Connor College of Law at ASU through World...

Read More...

Personalized Medicines Market 2020- Applications, Challenges, Growth, Shares, Trends, Top Players and Forecast to 2026 with key players position (3G…

January 31st, 2021 2:45 am

The Personalized Medicines Market grew in 2019, as compared to 2018, according to our report, Personalized Medicines Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Personalized Medicines Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025.

Deep analysis about Personalized Medicines Market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Personalized Medicines Market

Get a Sample Copy of the Report at: https://i2iresearch.com/download-sample/?id=16521

The Personalized Medicines Market is analysed based on product types, major applications and key players

Key product type:PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

Key applications:Hospitals PharmaciesRetail PharmaciesDietary Care CentersOthers

Key players or companies covered are:3G BiotechQuest DiagnosticsLaboratory Corporation of AmericaAbbottAgendia NVAsuragen IncBecton DickinsonCardioDx Inc.Foundation MedicineQiagenSiemens HealthcareAmgenBristol-Myers SquibbGE HealthcarePfizerSanofi23andMeIllumina

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/need-customization/?id=16521

Key questions answered in the report:1. What is the current size of the Personalized Medicines Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Personalized Medicines Market?4. What is the likely market forecast & how will be Personalized Medicines Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Personalized Medicines Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

https://neighborwebsj.com/

Continued here:
Personalized Medicines Market 2020- Applications, Challenges, Growth, Shares, Trends, Top Players and Forecast to 2026 with key players position (3G...

Read More...

West Belfast woman to be remembered in special TV documentary – Belfast Live

January 29th, 2021 2:55 am

An emotional programme is set to air about West Belfast woman Eimear Gooderham who passed away in 2019.

She sadly died after undergoing a stem cell transplant as part of her cancer treatment.

UTV presenter Sarah Clarke first met Eimear back in 2018 when, with she and her family made a desperate appeal for more people to join the stem cell register.

This was Eimear's only hope, after the return of her cancer and her family members not being a match.

Sarah kept in touch with the family and, when a match was found, Eimear recorded video diaries charting her treatment in Dublin to be incorporated into a UTV programme about her journey.

Whilst the transplant itself was successful, Eimear sadly suffered complications from the treatment and passed away.

Eimear's Wish tells her story, much of it in her own words from extracts from her video diary.

Her Dad Sen and sister Seinn, share memories of Eimear, give their perspectives on what happened, talking about the positive ways they have been dealing with their grief since she passed away.

A consultant haematologist also gives an insight into the impact of stem cell transplants, and of the hope that this type of surgery can offer, with Sean reiterating that Eimear's Wish is to have more people sign up to the donor register.

Sen said: We hope the programme will highlight the need for more people in Northern Ireland to join the stem cell donor register, especially young men aged between 16 and 30.

"They produce more and stronger stem cells than any other group, and crucially they dont get pregnant, as women cant donate stem cells during pregnancy and for 12 months afterwards. There is also a lack of age-appropriate care for teenagers and young adults with life threatening illnesses such as blood cancer.

"The current facilities and the environment in which our teenagers and young adults receive their treatment and care is very poor. There also needs to be better facilities for the childrens carers.

Sarah added: It was Eimears dying wish to raise awareness of stem cell donation and to help further research into the treatment to help others. And although this programme is an entirely different one from the one we set out to make, I hope that it will in some way help to do that.

Are you a lover of Style, Beauty or Interiors? Maybe you want the latest tips on keeping fit, eating right, organising your home and staying well, not to mention all the latest showbiz goss and the craic around town? If that sounds right up your street then follow Belfast Live's brand new lifestyle page Be.

You can find us on Facebook ,Twitter and Instagram.

We at UTV are very grateful that Eimear herself, before her death, and Sen and Seinn, despite their grief, shared so much in the making of the programme creating a positive and lasting legacy in this remarkable young woman's memory."

Watch Up Close Eimears Wish on UTV on Thursday 28th January at 10.45pm and on catch up HERE.

View post:
West Belfast woman to be remembered in special TV documentary - Belfast Live

Read More...

UTV documentary tells of young Belfast woman’s lasting legacy to promote stem cell donation – The Irish News

January 29th, 2021 2:55 am

EIMEAR Gooderham (ne Smyth) was just 25 when she died peacefully in hospital with her family at her bedside.

It was just a week after she had married Phillip Gooderham in hospital and she was buried in the wedding dress she never got to wear.

Almost two years on, her family hope a television documentary about Eimear - a make-up artist from the Coolnasilla area of west Belfast - will help create a positive and lasting legacy in her memory.

The programme, due to be broadcast on UTV and presented by journalist Sarah Clarke, features Eimear's own video diaries, which she had hoped would raise awareness of a campaign for stem cell donors that she launched before her death.

Ms Clarke said the documentary had aimed to "follow Eimear's journey, treatment and her recovery".

"She was very open about her battle and while a lot of the programme is distressing, it shows how courageous Eimear was," she said.

Eimear was diagnosed with stage two Hodgkins Lymphoma, a type of blood cancer, in September 2016.

She underwent 12 cycles of intensive chemotherapy and was given the all-clear in spring 2017.

But the disease returned and in December that year, Eimear was treated with an autologous stem cell transplant, intensive chemotherapy and her own stem cells returned afterwards to rescue her bone marrow from the effect of the treatment.

Months later she was given the good news she was in remission, but the Hodgkins Lymphoma returned again and doctors said her best chance of survival was another stem cell transplant - this time from a donor.

With neither of her siblings a match, she desperately needed to find a stem cell donor.

Eimear and her father Sean launched an appeal to raise awareness of the stem cell register, which allows donors of the correct tissue types to be matched with patients.

Their campaign saw the number of people joining the register in Northern Ireland soar.

Determined to use her own experience to help others, Eimear began filming videos on her phone for the UTV documentary.

Her desire to show her cancer battle as well as her upbeat outlook on life are reflected in the diaries, with many filmed as she underwent treatment.

Speaking ahead of the broadcast tonight, Ms Clarke said her own family's cancer battle had also inspired her to tell Eimear's story.

"In 2017, my nephew Jack was diagnosed with leukaemia, aged just 15," she said.

"I remember my brother Simon, who is a doctor, saying they may have to pursue a stem cell transplant. He knew how difficult it would be to find a match and to endure.

"Fortunately Jack didn't need it, but he had to undergo a year of intensive chemo and four years of maintenance chemo.

"It was rough and a very difficult period and thankfully he's now in remission, but it made me relate to Eimear and San's appeal."

On October 31 2018 - a year before Eimear and Phillip had planned to marry - she received her stem cell transplant.

A video extract of the days after the operation shows Eimear describe how "it's been really rough", as the donor's cells began attacking her cells - a condition known as graft versus host disease.

Despite being discharged from hospital, months later she became ill again with complications associated with the transplant - she was losing her brave battle.

Phillip tells the programme: "I wanted to tell her it was going to be ok, but I didn't want to lie to her. I wanted it to be over so she wasn't in pain".

In June 2019, the couple tied the knot and Eimear got "her final wish".

"We had had it planned, we had to cancel our wedding so it was, in the most horrific circumstances, the nicest way to end her life, by her getting her final wish," said Phillip.

Eimear died on June 27 2019.

Since then her family have continued to campaign to raise awareness of stem cell donation.

Her father Sean said they hope the programme will "highlight the need for more people in Northern Ireland to join the stem cell donor register, especially young men aged between 16 and 30".

Sarah also said while the documentary is "not exactly the one we set out to make, its still one of hope and courage".

"It was Eimears dying wish to raise awareness of stem cell donation and to help further research into the treatment to help others," she said.

"She was adamant she wanted people to sign the register and raise awareness. Her family feel the onus is now on them to continue this.

"The programme pays tribute to a courageous young woman and her family's desire to create a positive and lasting legacy in her memory."

Up Close: Eimears Wish is on UTV at 10.45pm.

Link:
UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News

Read More...

L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL – Targeted Oncology

January 29th, 2021 2:55 am

During a Targeted Oncology Case Based Peer Perspectives Roundtable event, Loretta J. Nastoupil, MD, associate professor, director, Lymphoma Outcomes Database, section chief, New Drug Development, in the Department of Lymphoma/Myeloma, Division Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discussed the case of a 74-year-old patients with diffuse large B-cell lymphoma.

Targeted OncologyTM: What are the potential second- and third-line therapy options for this patient at this point in their treatment?

NASTOUPIL: The current NCCN [National Comprehensive Cancer Network] guidelines...look like a laundry list of a number of different therapeutic options and [do] not necessarily provide an algorithm for what might be the preferred choice based [on] certain patient characteristics.1 It just signifies that there may be several different chemoimmuno-therapy approaches and then even some potential targeted therapy approaches.

Then in the third line, CAR [chimeric antigen receptor] T-cell therapy becomes an option for patients.

Why is the tafasitamab and lenalidomide regimen listed in this poll? What is the rationale for combining these agents?

For those who may not be familiar, tafasitamab is a naked CD19 antibody, not a CAR T therapy. Its not an antibody-drug conjugate but a naked antibody engineered for enhanced ADCC [anti- body-dependent cellular cytotoxicity].

Tafasitamab and lenalidomide were approved in July 2020 for the treatment of DLBCL.2 Its an interesting label in that it is approved for patients who are not transplant candidates, and so that raises the question of how you define a nontransplant candidate. Its approved in combination withlenalidomide, 25 mg dosed 1 through 21 of a 28-day cycle; the lenalidomide is continued for a maximum of 12 cycles, but the tafasitamab is continued as monotherapy until disease progression or intolerance.

Tafasitamab was engineered for enhanced ADCC and direct cell death. Investigators saw encouraging activity in a phase 1 trial as a single agent. Then the rationale for combination with lenalidomide is because of the enhanced ADCC and because of activity seen with rituximab [Rituxan] and lenalidomide across a number of B-cell lymphoma subtypes. It was felt that this might be an interesting synergistic combination, and then [investigators] set out to explore it further in this phase 2 study in relapsed/refractory DLBCL.

Which trial looked at this combination, and what was the design?

The L-MIND study [NCT02399085] was an open-label, multi-center study.3 [Investigators] evaluated patients with relapsed/ refractory DLBCL. Now some important eligibility criteria are worth noting. They restricted eligibility to patients who had had 1 to 3 prior lines of therapy, so this is not a heavily pretreated patient population.

Patients who were ineligible for high-dose chemotherapy or autologous stem cell transplant were evaluated. There are not agreed-upon criteria for whos not a transplant candidate, other than failing to have chemotherapy-sensitive disease. But because this [trial] would enroll patients whod only had 1 prior line of therapy, that opens the discussion to how you would define a nontransplant candidate. This was done in a number of European sites where age alone is a factor, so generally patients over the age of 70 are deemed not appropriate candidates for stem cell transplant; its one of the more common criteria that were applied for defining this patient population.

The study schema outlined the dosing of lenalidomide at 25 mg [daily], which is standard in multiple myeloma studies. Its a bit higher than the standard dosing done in most Hodgkin or non-Hodgkin lymphoma studies and speaks to the evolution of treatment over time, particularly when weve combined [lenalidomide] with other agents. Most of the time were starting at 20 mg, but for the purposes of this study, in the schema it was 25 mg of lenalidomide.

Its also important to note that there was an induction phase with the combination, and particularly during cycle 1, tafasitamab was dosed weekly with an additional loading dose on day 4 of cycle 1 and then continued weekly up to all 3 cycles so 12 weeks of treatment. Beyond cycle 3, it was dosed every other week or every 2 weeks until disease progression or intolerance. The primary end point of the study was objective response rate [ORR] as assessed by independent central review, and then key secondary end points included progression-free survival [PFS], duration of response [DOR], and overall survival [OS], in addition to safety.

There were 81 patients enrolled on the single-arm phase 2 study, and that speaks to the fact that lymphoma is a rare tumor type. The median age was 72, again [considering] that age over 70 was one of the most common criteria utilized to define a nontransplant candidate. About 51% of the patient population had an IPI risk score of 3 or higher, 75% had advanced-stage disease, median number of prior lines of therapy was 2, and primary refractory [disease] comprised only about 19% of the patient population. These patients generally were not primary refractory, though [the trial] did include some. Prior stem cell transplant patients might be a poor transplant candidate because theyve already had transplant; [these patients comprised] about 11% of the patient population.

What were the efficacy data seen in the L-MIND study?

The ORR determined by the independent central review was quite notable. The ORR in patients with relapsed/refractory DLBCL was 60%, and the complete response rate was 43%. Probably even more important is that it appeared to be durable. The median DOR was 21.7 months. It was not reached among those patients who achieved a complete response, which was almost half the study population....DOR for patients who had a partial response [was markedly lower at] only 4.4 months, and 72% of [all] patients had an ongoing response beyond 12 months.

Importantly, there was a PFS in this patient population of 12.1 months, and median OS had not been reached. At 18 months, 64% of the patient population was still alive. I think this is important because if you put this into context, prior to the introduction of CAR T, if we look at the SCHOLAR-1 datawhich were of a retrospective analysis of patients treated at MD Anderson Cancer Center, at Mayo Clinic, and in the Lysa group, which is a large French group the median OS...was 6 months for patients with relapsed/ refractory DLBCL in second line or later.4 Again, this is a marked improvement over that.

The median PFS is also quite notable at 12 months [at 50%] because the median PFS for the CAR T population was only about 6 months. Now this probably reflects a specific patient population in that most of these patients were not as heavily pretreated as the CAR T population. A small percent- age were primary refractory.

Are other studies in the DLBCL setting looking at this regimen?

There were data reported at the 2020 American Society of Clinical Oncology Annual Meeting [from] the RE-MIND study [NCT04150328]....They essentially compared [the L-MIND] results with a synthetic control where they captured retrospective data of single-use lenalidomide in relapsed/refractory DLBCL and then tried to match that in terms of baseline characteristics.5

It looks like [the combination] was at least a significant improvement over lenalidomide monotherapy. Then the question is really: Is it better than the other options currently available in the relapsed DLBCL space? And that hasnt been answered. Its moving into front line. The phase 1b data were reported. Theres a randomized study that is launching, so that will then raise the question of how we sequence treatment in DLBCL.

What was the toxicity profile of tafasitamab and lenalidomide for these patients?

The most common adverse events [AEs] were neutropenia, anemia, and thrombocytopenianot surprising to me because again this is an antibody in combination with lenalidomide.3 Grade 3 or higher neutropenia occurred in 48% of patients and grade 3 or higher thrombocytopenia in 17% of patients. Fortunately, febrile neutropenia was not high. There was 10% with grade 3 and 2% with grade 4. Growth factor use was at the discretion of the treating physician. It was not built into the protocol in terms of prophylactic use.

For the most common AEs that were nonhematologic, [what was noticeable was] the vast majority were grade 1/2, though about 9% of patients had a grade 3 rash, which is not unusual for lenalidomide in lymphoma. One percent had grade 3 diarrhea, and about 5% had hypokalemia. Some of that might be related to diarrhea and some nausea. Cough was about 1% at grade 3 or higher, and bronchitis was 1% at grade 4. Fatigue was another common AE, with 15% at grade 1 or 2.

Serious AEs occurred in 51% of the study population, although 19% were attributed to the study drug; 12% discontinued therapy as a result of toxicity, and then 9% had an AE of special interest. The AEs of special interest included tumor flare in 3 patients, and 1 patient with grade 2 basal cell carcinoma. Grade 3 [allergic dermatitis] occurred in 3 patients. There were 13% who had a treatment-emergent AE that led to death; however, according to the [investigators], none [of the deaths] were thought to be related to study treatment. The severity and incidence of the toxicities after lenalidomide was discontinued decreased, suggesting that a lot of the toxicity was due to the combination and not the CD19 monotherapy.

Read this article:
L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology

Read More...

Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes…

January 29th, 2021 2:55 am

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND, enabling the company to proceed with initiating a clinical trial for VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell therapy to treat T1D. Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2021 in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia.

As we celebrate the 100th anniversary of the discovery of insulin this year, we are excited to bring a first-in-class cell therapy to the clinic with the potential to meaningfully impact people living with T1D, said Bastiano Sanna, Ph.D., Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. We look forward to getting our clinical program underway and testing our unique approach of replacing pancreatic islet cells, which are destroyed in people with type 1 diabetes, with our stem cell-derived fully differentiated insulin-producing pancreatic islet cells.

About VX-880VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the bodys ability to regulate glucose levels by restoring pancreatic islet cell function, including insulin production.

The VX-880 clinical trial will involve an infusion of fully differentiated, functional islet cells, as well as the chronic administration of concomitant immunosuppressive therapy, to protect the islet cells from immune rejection.

About the Phase 1/2 Clinical TrialThe clinical trial is a Phase 1/2, single-arm, open-label study in subjects who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. This will be a sequential, multi-part clinical trial to evaluate the safety and efficacy of different doses of VX-880. Approximately 17 patients will be enrolled in the clinical trial.

About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing islet cells in the pancreas, leading to loss of insulin production and impairment of blood glucose control. The absence of insulin leads to abnormalities in how the body processes nutrients, leading to high blood glucose levels. High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in patients with T1D. Hypoglycemia remains a critical limiting factor in glycemic management, and severe hypoglycemia can cause loss of consciousness, coma, seizures, injury, and can be fatal.

There are currently limited treatment options beyond insulin for the management of T1D.

About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Bastiano Sanna, Ph.D., in this press release, statements regarding the development, plans and expectations for our T1D pipeline program, including our plans to initiate a Phase 1/2 clinical trial in people with T1D and expected timeline of our clinical trials, statements regarding patient enrollment and dosing, statements regarding potential clinical trial results and anticipated benefits of VX-880, and our plans to provide further updates on our T1D pipeline program. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the FDA may not approve our IND, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's development programs may not support registration or further development due to safety, efficacy or other reasons, that the COVID-19 pandemic may impact the status or progress of our clinical trials, and other risks listed under the heading Risk Factors in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at http://www.sec.gov and available through the company's website at http://www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Link:
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes...

Read More...

If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? – Kaiser Health News

January 29th, 2021 2:55 am

Judith Graham

This story also ran on CNN. It can be republished for free.

As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines appropriateness for older adults with various illnesses. Among them are cancer patients receiving active treatment, dementia patients near the end of their lives and people with autoimmune conditions.

Recently, a number of readers have asked me whether older relatives with these conditions should be immunized. This is a matter for medical experts, and I solicited advice from several. All strongly suggested that people with questions contact their doctors and discuss their individual medical circumstances.

Experts advice may be helpful since states are beginning to offer vaccines to adults over age 65, 70 or 75, including those with serious underlying medical conditions. Twenty-eight states are doing so, according to the latest survey by The New York Times.

Q: My 80-year-old mother has chronic lymphocytic leukemia. For weeks, her oncologist would not tell her yes or no about the vaccine. After much pressure, he finally responded: It wont work for you, your immune system is too compromised to make antibodies. She asked if she can take the vaccine anyway, just in case it might offer a little protection, and he told her he was done discussing it with her.

First, some basics. Older adults, in general, responded extremely well to the two covid-19 vaccines that have received special authorization from the Food and Drug Administration. In large clinical trials sponsored by drugmakers Pfizer and Moderna, the vaccines achieved substantial protection against significant illness, with efficacy for older adults ranging from 87% to 94%.

But people 65 and older undergoing cancer treatment were not included in these studies. As a result, its not known what degree of protection they might derive.

Dr. Tobias Hohl, chief of the infectious diseases service at Memorial Sloan Kettering Cancer Center in New York City, suggested that three factors should influence patients decisions: Are vaccines safe, will they be effective, and what is my risk of becoming severely ill from covid-19? Regarding risk, he noted that older adults are the people most likely to become severely ill and perish from covid, accounting for about 80% of deaths to date a compelling argument for vaccination.

Regarding safety, there is no evidence at this time that cancer patients are more likely to experience side effects from the Pfizer-BioNTech and Moderna vaccines than other people. Generally, we are confident that these vaccines are safe for [cancer] patients, including older patients, said Dr. Armin Shahrokni, a Memorial Sloan Kettering geriatrician and oncologist.

The exception, which applies to everyone, not just cancer patients: people who are allergic to covid-19 vaccine components or who experience severe allergic responses after getting a first shot shouldnt get covid-19 vaccines.

Efficacy is a consideration for patients whose underlying cancer or treatment suppresses their immune systems. Notably, patients with blood and lymph node cancers may experience a blunted response to vaccines, along with patients undergoing chemotherapy or radiation therapy.

Even in this case, we have every reason to believe that if their immune system is functioning at all, they will respond to the vaccine to some extent, and thats likely to be beneficial, said Dr. William Dale, chair of supportive care medicine and director of the Center for Cancer Aging Research at City of Hope, a comprehensive cancer center in Los Angeles County.

Balancing the timing of cancer treatment and immunization may be a consideration in some cases. For those with serious disease who need therapy as quickly as possible, we should not delay [cancer] treatment because we want to preserve immune function and vaccinate them against covid, said Hohl of Memorial Sloan Kettering.

One approach might be trying to time covid vaccination in between cycles of chemotherapy, if possible, said Dr. Catherine Liu, a professor in the vaccine and infectious disease division at Fred Hutchinson Cancer Research Center in Seattle.

In new guidelines published late last week, the National Comprehensive Cancer Network, an alliance of cancer centers, urged that patients undergoing active treatment be prioritized for vaccines as soon as possible. A notable exception: Patients whove received stem cell transplants or bone marrow transplants should wait at least three months before getting vaccines, the group recommended.

The American Cancer Societys chief medical and scientific officer, Dr. William Cance, said his organization is strongly in favor of cancer patients and cancer survivors getting vaccinated, particularly older adults. Given vaccine shortages, he also recommended that cancer patients who contract covid-19 get antibody therapies as soon as possible, if their oncologists believe theyre good candidates. These infusion therapies, from Eli Lilly and Co. and Regeneron Pharmaceuticals, rely on synthetic immune cells to help fight infections.

Q: Should my 97-year-old mom, in a nursing home with dementia, even get the covid vaccine?

The federal government and all 50 states recommend covid vaccines for long-term care residents, most of whom have Alzheimers disease or other types of cognitive impairment. This is an effort to stem the tide of covid-related illness and death that has swept through nursing homes and assisted living facilities 37% of all covid deaths as of mid-January.

The Alzheimers Association also strongly encourages immunization against covid-19, both for people [with dementia] living in long-term care and those living in the community, said Beth Kallmyer, vice president of care and support.

What I think this question is trying to ask is Will my loved one live long enough to see the benefit of being vaccinated? said Dr. Joshua Uy, medical director at a Philadelphia nursing home and geriatric fellowship director at the University of Pennsylvanias Perelman School of Medicine.

Potential benefits include not becoming ill or dying from covid-19, having visits from family or friends, engaging with other residents and taking part in activities, Uy suggested. (This is a partial list.) Since these benefits could start accruing a few weeks after residents in a facility are fully immunized, I would recommend the vaccine for a 97-year-old with significant dementia, Uy said.

Minimizing suffering is a key consideration, said Dr. Michael Rafii, associate professor of clinical neurology at the University of Southern Californias Keck School of Medicine. Even if a person has end-stage dementia, you want to do anything you can to reduce the risk of suffering. And this vaccine provides individuals with a good deal of protection from suffering severe covid, he said.

My advice is that everyone should get vaccinated, regardless of what stage of dementia theyre in, Rafii said. That includes dementia patients at the end of their lives in hospice care, he noted.

If possible, a loved one should be at hand for reassurance since being approached by someone wearing a mask and carrying a needle can evoke anxiety in dementia patients. Have the person administering the vaccine explain who they are, what theyre doing and why theyre wearing a mask in clear, simple language, Rafii suggested.

Q: Im 80 and I have Type 2 diabetes and an autoimmune disease. Should I get the vaccine?

There are two parts to this question. The first has to do with comorbidities having more than one medical condition. Should older adults with comorbidities get covid vaccines?

Absolutely, because theyre at higher risk of becoming seriously ill from covid, said Dr. Abinash Virk, an infectious diseases specialist and co-chair of the Mayo Clinics covid-19 vaccine rollout.

Pfizers and Modernas studies specifically looked at people who were older and had comorbidities, and they showed that vaccine response was similar to [that of] people who were younger, she noted.

The second part has to do with autoimmune illnesses such as lupus or rheumatoid arthritis, which also put people at higher risk. The concern here is that a vaccine might trigger inflammatory responses that could exacerbate these conditions.

Philippa Marrack, chair of the department of immunology and genomic medicine at National Jewish Health in Denver, said theres no scientifically rigorous data on how patients with autoimmune conditions respond to the Pfizer and Moderna vaccines.

So far, reasons for concern havent surfaced. More than 100,000 people have gotten these vaccines now, including some who probably had autoimmune disease, and theres been no systematic reporting of problems, Marrack said. If patients with autoimmune disorders are really worried, they should talk with their physicians about delaying immunization until other covid vaccines with different formulations become available, she suggested.

Last week, the National Multiple Sclerosis Society recommended that most patients with multiple sclerosis another serious autoimmune condition get the Pfizer or Moderna covid vaccines.

The vaccines are not likely to trigger an MS relapse or to worsen your chronic MS symptoms. The risk of getting COVID-19 far outweighs any risk of having an MS relapse from the vaccine, it said in a statement.

Were eager to hear from readers about questions youd like answered, problems youve been having with your care and advice you need in dealing with the health care system. Visitkhn.org/columniststo submit your requests or tips.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

This story can be republished for free (details).

Read more here:
If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News

Read More...

Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment – Business Wire

January 29th, 2021 2:55 am

MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company appointed Ms. Belen Toledo MSc., a biotechnologist specializing in cell regenerative medicine, to evaluate the impact of proenzyme therapy on the tumor microenvironment. Ms. Toledos work will be part of the Proenzymes Optimization Project 1 (POP1) Joint Research and Drug Discovery Program designed to produce synthetic recombinant, commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen.

Ms. Toledo, will elucidate molecular pathways involved in the proenzymes anti-tumor efficacy and study how they interact with the pre-metastatic tumor niche, focusing on the interaction and suppression of tumor associated cells, like cancer-associated fibroblasts and macrophages. A pre-metastatic tumor niche is an environment in a secondary organ conducive to the metastasis (spreading) of a primary tumor. Such a niche provides favorable conditions for growth, and eventually metastasis, in an otherwise foreign and hostile environment for the primary tumor cells. Metastasis remains the main cause of patient death from solid tumors for cancer sufferers. To achieve this, Ms. Toledo will use integrated tumor models in a microfluidics chip by obtaining 3-dimensional bio-impressions of tumor cells from patients with advanced solid tumors, developed at the Centre for Biomedical Research, University of Granada, Granada, Spain, led by Prof. Juan Marchal M.D.

Belen Toledo is a very capable biotechnologist who is excited about the project and its potential as a novel approach for the prevention and treatment of metastatic cancer. We look forward to exploring the potential of proenzyme therapy, which is groundbreaking research, said Prof. Macarena Pern, Ph.D., Lecturer and Joint Research Supervisor from Jan University.

The application of 3D tumor models on-a-chip will allow us to faithfully recreate tumor heterogeneity and stroma-tumor interactions. We aim to evaluate the effect of proenzyme therapy on effective personalized therapy models, generated from a small biopsy of patients, said Prof. Juan Antonio Marchal M.D., Joint Research Supervisor from Granada University.

Evaluating the effects of proenzyme therapy in the tumor microenvironment is critically important, as it tells us the drug is able to penetrate into this target area and exert its effects. At the same time, it confirms the selectivity of the drug on solid tumors, by targeting cancer cells and leaving healthy cells alone. The scientific implications provide us with confidence that our drug is effective and less toxic compared to standard treatment approaches, said Dr. Julian Kenyon M.D., Propancs Chief Scientific Officer and Joint Research Supervisor.

The POP1 program is designed to produce a backup clinical compound to the Companys lead product candidate, PRP. The objective is to produce large quantities of trypsinogen and chymotrypsinogen for commercial use that exhibits minimal variation between lots and without sourcing the proenzymes from animals. Propanc is undertaking the challenging research project in collaboration with the Universities of Jan and Granada, led by research scientists Mr. Aitor Gonzlez MSc. and Ms. Toledo, supported by Profs. Pern and Marchal, representing the Universities and Dr. Kenyon.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the Company) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit http://www.propanc.com.

The Companys novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the bodys primary defense against cancer.

To view the Companys Mechanism of Action video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements, which may often, but not always, be identified by the use of such words as may, might, will, will likely result, would, should, estimate, plan, project, forecast, intend, expect, anticipate, believe, seek, continue, target or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Companys ability to continue as a going concern absent new debt or equity financings; the Companys current reliance on substantial debt financing that it is unable to repay in cash; the Companys ability to successfully remediate material weaknesses in its internal controls; the Companys ability to reach research and development milestones as planned and within proposed budgets; the Companys ability to control costs; the Companys ability to obtain adequate new financing on reasonable terms; the Companys ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Companys ability to obtain and maintain patent protection; the Companys ability to recruit employees and directors with accounting and finance expertise; the Companys dependence on third parties for services; the Companys dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Companys Registration Statement on Form S-1, Amendment No. 5, filed with the U.S. Securities and Exchange Commission (the SEC) on November 3, 2020, and in the Companys other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

More:
Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment - Business Wire

Read More...

Experimental taphonomy of organelles and the fossil record of early eukaryote evolution – Science Advances

January 29th, 2021 2:55 am

Abstract

The timing of origin of eukaryotes and the sequence of eukaryogenesis are poorly constrained because their fossil record is difficult to interpret. Claims of fossilized organelles have been discounted on the unsubstantiated perception that they decay too quickly for fossilization. We experimentally characterized the pattern and time scale of decay of nuclei, chloroplasts, and pyrenoids in red and green algae, demonstrating that they persist for many weeks postmortem as physical substrates available for preservation, a time scale consistent with known mechanisms of fossilization. Chloroplasts exhibit greater decay resistance than nuclei; pyrenoids are unlikely to be preserved, but their presence could be inferred from spaces within fossil chloroplasts. Our results are compatible with differential organelle preservation in seed plants. Claims of fossilized organelles in Proterozoic fossils can no longer be dismissed on grounds of plausibility, prompting reinterpretation of the early eukaryotic fossil record and the prospect of a fossil record of eukaryogenesis.

The origin of eukaryotes is among the most formative of events in Earth history, facilitating the emergence of complex multicellular life. However, almost every aspect of eukaryogenesis has proven controversial, not least the sequence of acquisition of eukaryotic characters and the timing of origin of crown eukaryotes (1). The last eukaryote common ancestor (LECA) would have had all fundamental eukaryotic characteristics, including a complex cytoskeleton, nucleus, mitochondria, and other membrane-bound organelles, but when and in what order these traits were acquired before LECA is uncertain. The fossil record has been effectively silent on these issues, in part because of the challenge of identifying early fossil eukaryotes, which have conventionally been discriminated on the basis of size, cyst wall complexity, and circumstantial evidence of a cytoskeleton (2). Unfortunately, none of these criteria are definitive, since the size distinction from prokaryotes is probabilistic, not deterministic, and an actin cytoskeleton is an ancestral feature of archaea, not a eukaryotic innovation (3). Thus, the challenge of discriminating stem from crown eukaryotes, as well as eukaryotes from prokaryotes, appears insurmountable (4). Fossilized organelles would provide a more definitive criterion for identifying eukaryote-grade fossils, as well as informing on the evolutionary assembly of eukaryotes and the timing of emergence of the fundamental clades of photosynthetic eukaryotes. While there are many claims of fossilized nuclei and other organelles through the Proterozoic and Phanerozoic [e.g., (514)], their identification is often contentious and many are instead interpreted as collapsed cytoplasmic remains. This null interpretation stems largely from classical experiments in which the cytoplasm of decaying bacteria collapsed into small dense structures that resemble nuclei (15, 16), and it is now commonly held that organelles cannot fossilize because they decay too quickly (13). However, there is no experimental evidence to support this view, and there are unequivocal records of intracellular organelles from the recent geologic past (510). Taphonomy experiments characterize patterns of decay, providing an interpretative model for the fossil record. These experiments have previously aided interpretation of Ediacaran Wengan embryo-like fossils, demonstrating the feasibility of fossilizing embryos and precluding the interpretation of these fossils as giant sulfur bacteria (17, 18). Here, we undertake taphonomy experiments on eukaryotic organelles to complement classical experiments on bacterial-grade cells, to test the general view that organelles decay too rapidly to be fossilized.

We performed taphonomy experiments on four species of algae: the unicellular green alga Chlorella sp., the colonial green algae Volvox aureus and Pandorina morum, and the multicellular red alga Rhodochorton sp. These species reflect different ecologies and evolutionary grades: freshwater (green algae) versus marine (red alga), unicellularity (Chlorella) versus multicellularity, large colony size (V. aureus) versus small colony size (P. morum), and pyrenoids (green algae) versus none (red alga). Sampling across Rhodophyta and Viridiplantae facilitates a test of consistency among the results. The algae were euthanized in -mercaptoethanol (BME) to prevent autolysis (18) and allowed to decay for 6 weeks in either fresh water (the green algae) or artificial seawater (Rhodochorton), reflecting their natural ecology. We performed parallel experiments under oxic and anoxic conditions to control for the effects of aerobic microbial activity; there was no difference in the patterns of decay between the two groups, but anoxic conditions exhibited slower rates in agreement with previous taphonomy experiments (19, 20). Periodic sampling allowed the identification of sequences of decay in the organelles (Fig. 1). The time span of the experiments was chosen to exceed that required for exceptional fossil preservation through phosphate or silica mineral replication, two mineral systems that facilitate fossilization with subcellular fidelity [e.g., (21)].

Acquisition of different features as decay progresses in oxic and anoxic groups. Samples were taken while the algae were alive (L), immediately after death (FK), and every 2 to 3 days for 6 weeks. The development of holes in Rhodochorton was particularly noticeable, and so this was measured separate from the collapse of the chloroplast edges. In P. morum, the cells themselves collapsed after death.

Cells of V. aureus are broadly the same as those of the closely related P. morum, but colonies contain anywhere from 500 to 10,000 cells held in place by a complex network of cytoplasmic bridges and extracellular matrix (Fig. 2A) (22). After death, the colonies maintained their general shape for several weeks, although the cells gradually became less evenly spaced and the colonies deformed (Fig. 2B). Some colonies ruptured, while others formed large, misshapen conglomerates (Fig. 2B). Within the cells, the chloroplasts and nuclei remained after 6 weeks, although nuclei usually disappeared before chloroplasts (Figs. 1 and 2, C and E). Pyrenoids were the least decay resistant, although their surrounding starch grain ring persisted (Fig. 2, D and E). Chloroplasts deformed as they decayed, thinning and perforating before fragmenting and disappearing (Fig. 2F), but nuclei were more consistent in appearance (Fig. 2, C and E).

(A to F) V. aureus and (G to L) P. morum. Living colonies of V. aureus (A) show clear cell boundaries and structure, but after death, the colonies display some disaggregation (B). As decay progresses, chloroplasts become less regular in shape (C and E) and develop holes and thin patches (F). Pyrenoids disappear from within the chloroplast, leaving holes ringed by starch grains with no pyrenoid visible (D and E). Some nuclei were still visible weeks after death with no evidence of deformation (C and E). Living colonies of P. morum are closely arranged (G), but this collapses after cell death, resulting in the loss of Y-shaped junctions (H). One chloroplast was observed leaving the cell in a cloud (I), but usually, chloroplasts developed holes and thin patches as they decayed (J and K). In late stages of decay, small amounts of green chloroplast were left surrounding the remnants of the starch grain ring (L). Nuclei could still be observed well into decay (K and L). Pyrenoids decayed quickly to leave empty starch grain rings, but this varied within colonies, with some cells still with visible pyrenoids (J and L). n, nucleus; c, chloroplast; s, starch grain ring; p, pyrenoid; y, Y-shaped junction; t/h, thinning/holes within the chloroplast. The number of days postmortem is indicated in the top right corner. Scale bars, 50 m (A), 91.4 m (B), 9.1 m (C), 9.0 m (D), 9.0 m (E), 9.1 m (F), 7.8 m (G), 6.3 m (H), 9.1 m (I), 9.1 m (J), 9.1 m (K), and 9.0 m (L).

Colonies of P. morum are composed of between 4 and 32 cells with Y-shaped junctions (Fig. 2G) (22). Each has a single cup-shaped chloroplast occupying most of the volume, one to several pyrenoids, several vacuoles, and a nucleus in the gap left by the shape of the chloroplast (22). The colonies started to collapse immediately after death; cells decreased in volume and separated, leading to loss of the Y-shaped junctions (Fig. 2H). Nuclei were still visible and undeformed 6 weeks postmortem, although their abundance decreased (Figs. 1 and 2, K and L). Chloroplasts were the most decay resistant of the organelles analyzed, present in many cells after 6 weeks, but showed evidence of deformation: irregular edges, holes, and thinned areas developed before the chloroplast ultimately fragmented and became indiscernible (Fig. 2, J to L). Pyrenoids were the least decay resistant, decaying within 3 weeks and leaving a hole in the chloroplast. No pyrenoids were observed without the chloroplast, but the starch grain ring that surrounds the pyrenoid was very decay resistant, often observed as an isolated ring after the rest of the cell contents decayed away (Fig. 2, J and L).

Unicellular Chlorella is similar to component cells of colonial Pandorina and Volvox: A large cup-shaped chloroplast with a single pyrenoid occupies most of the cell, with a nucleus and vacuoles in the gap (Fig. 3A) (22). Immediately after death, cells showed little or no evidence of change (Fig. 3B). Nuclei were visible throughout the 6 weeks and showed no evidence of degradation (Fig. 3, C, F and G). Pyrenoids were the least decay resistant, while chloroplasts were the most decay resistant (Fig. 1). Chloroplasts occasionally escaped the cell during decay if the cell ruptured early (Fig. 3F). Otherwise, chloroplasts collapsed, producing irregular edges before developing holes, thinning, fragmenting, and disaggregating (Fig. 3, C to F).

(A to G) Chlorella sp. and (H to N) Rhodochorton sp. Living cells of Chlorella (A) show little difference from those immediately after death (B). As decay progresses, chloroplasts collapse, becoming less regular in shape (C and D). Pyrenoids disappear quickly, leaving empty starch grain rings (E), while chloroplasts thin and develop holes (D to F). Nuclei could still be observed in some cells (C, F, and G). In some cases, the chloroplast can escape the cell (F). Living Rhodochorton cells (H) also show little difference from those immediately after death, although chloroplasts collapse and deform quickly (I). Holes develop within the chloroplasts (J and K) and in later stages of decay can occasionally conglomerate along the cell walls along with the cytoplasmic contents (L) or pull away from the cell wall (M). Nuclei can still be observed in some cells, even when much of the cytoplasm is gone (K and N). The number of days postmortem is indicated in the top right corner. Scale bars, 10 m (A), 18.7 m (B), 15 m (C), 18.5 m (D), 18.4 m (E), 15.8 m (F), 18.7 m (G), 12.6 m (H), 11.8 m (I), 14.9 m (J), 15.4 m (K), 14.1 m (L), 10.4 m (M), and 14.8 m (N).

The filamentous red alga Rhodochorton has cells with a central nucleus and two to three discoid chloroplasts that do not have pyrenoids (Fig. 3H) (23). The color and texture of the cytoplasm often obscure view of the nucleus, but nuclei could still be observed in some cells 6 weeks postmortem (Fig. 3, K and N). However, chloroplasts collapsed quickly, as evidenced by the irregular edges and discoid shapes, before forming holes and fragmenting (Fig. 3, I to K). These deformed chloroplasts remained in the cells for the full 6 weeks. The holes that developed were often in the center of the chloroplast, resulting in ring-shaped remains, but could also form along the edges (Fig. 3, J and K). As decay progressed, the cytoplasmic contents sometimes condensed along the edges of the cell, with fragments of chloroplast within (Fig. 3, L and M).

Claims of ancient fossilized intracellular organelles have generally been rejected, despite similarity in size, shape, and locus to organelles in living eukaryotes, on the basis of the following: (i) The composition of nuclei and other organelles (water, proteins, and nucleic acids) indicates that they will degrade rapidly after death, and (ii) if one organelle is preserved, then others should also (13). Our taphonomy experiments were designed not to simulate fossilization but, rather, to determine whether eukaryotic organelles persist postmortem as physical structures on a time scale compatible with permineralization, mineral replication, or stabilization as organic remains. Fossilization can progress rapidly: Phosphatization and silicification can occur within weeks of death (21).

Our experimental results demonstrate that organelles undergo broadly the same patterns of decay over similar time scales in all four algal species. Nuclei were resistant to notable deformation during decay, whereas chloroplasts underwent extensive changes: Irregular edges, holes, thin patches, and fragmentation occurred before full disintegration. However, chloroplasts, in particular, and nuclei, to a lesser extent, could still be observed in cells 6 weeks after death. The decrease in frequency of nuclei over decay time may be due to chloroplast collapse in the green algae, obscuring or engulfing nuclei, and the rough texture of the cytoplasm in Rhodochorton, which obscures identification of nuclei even in living cells. Pyrenoids disappeared quickly, but evidence of their presence remained in the form of the hole within the starch grain ring, often the last remaining structure in a decaying cell. These results agree with previous studies using Allium cepa (onion), which showed that nuclei can persist as physical structures on time scales compatible with their mineral replication (21, 24), although we observed no deformation of nuclei. Given that our experimental models include marine and freshwater species, unicellular and multicellular species, as well as representatives of two of the fundamental scions of Archaeplastida (Rhodophyta and Viridiplantae), it is reasonable to conclude that these observations can be generalized. The available experimental evidence indicates that claims of fossil eukaryotic organelles should be taken seriously.

There are numerous compelling claims of fossil nuclei, chloroplasts, and even mitochondria in Cenozoic plant remains that preserve histological detail of organelle structure (610, 25), and some of which even remain biochemically reactive to specific histological stains (6, 9, 10). In mummified Eocene Metasequoia leaves, the least degraded chloroplasts had clear thylakoid membranes and grana stacks, while the more degraded specimens showed evidence of chloroplast fragmentation, as seen in our experiments (9). Similarly, amber has yielded exquisitely preserved chloroplasts that are almost indistinguishable from living chloroplasts, with no loss of shape or structure (6, 25). Miocene angiosperm leaves (Fig. 4A) from the Clarkia beds of Idaho (USA) are among the best studied, revealing that chloroplasts and cell walls are more decay resistant than nuclei since they are present in the fossils more frequently (26, 27). However, nuclei have been described from the stem of a Jurassic fern (Fig. 4B) (5) and within Carboniferous gymnosperm pollen (28), demonstrating that they can be preserved. These empirical observations are consistent with our experimental results: Chloroplasts are the most decay resistant of organelles, but nuclei persist for a considerable length of time postmortem. Mode of preservation has also played a role in preserving these organelles; the Clarkia beds were preserved by volcanic ash, leading to desiccation before preservation as organic fossils (29), while the Jurassic fern was permineralized rapidly by hydrothermal vents (5). The less well-preserved Carboniferous gymnosperm nuclei were from coal balls that would not have fossilized as rapidly as the fern or the Miocene gymnosperms and angiosperms (28).

(A) Fossil of a Zelkova leaf from the Miocene Succor Creek Formation showing a chloroplast adpressed to the cell wall, with grana stacks visible and a densely stained starch grain. Transmission electron micrograph after a carbohydrate cytochemical analysis; image from (29) courtesy of Karl Niklas, Cornell University. (B) Segment of the stem of a royal fern from Jurassic deposits with clear nuclei in each cell. Light micrograph; image courtesy of Benjamin Bomfleur, University of Mnster. (C) Tomographic virtual section through Megasphaera, a fossil from the Wengan Biota that is suggested to have nuclei. Data courtesy of (35). (D) Intracellular structures in the holotype of R. chitrakootensis have previously been interpreted as pyrenoids but are unlikely to be so. Tomographic reconstruction; data from (41) courtesy of Stefan Bengtson, Swedish Museum of Natural History. (E) Bangiomorpha pubescens, currently considered the oldest crown eukaryote. Light micrograph; image courtesy of Nicholas Butterfield, University of Cambridge. (F) Caryosphaeroides and (G) Glenobotrydion from the Bitter Springs Biota have been suggested to be early eukaryotes with putative nuclei or chloroplasts. Light micrographs; images from (38) courtesy of SEPM. (H) Shuiyousphaeridium and (I) Dictyosphaera from the Ruyang Group, putative early eukaryotes with intracellular structures suggested to be nuclei or collapsed cellular contents. Light micrographs; images courtesy of Shuhai Xiao, Virginia Tech. (J) Leptoteichos from the Gunflint Iron Formation with a putative nucleus. Light micrograph; image from (45) courtesy of SEPM (Society for Sedimentary Geology) (SEPM). Scale bars, 1.4 m (A), 25.6 m (B), 250 m (C), 38.2 m (D), 25 m (E), 3.3 m (F), 13.8 m (G), 14.3 m (H), 25.3 m (I), and 3.5 m (J).

Wengan embryoids: Bacteria, holozoans, or algae?. Intracellular structures in Wengan phosphatic embryo-like fossils (Fig. 4C) have been central to debate over their affinity. The interpretation of intracellular structures as nuclei precludes a bacterial interpretation (30), favoring affinity with metazoans (31) or nonmetazoan holozoans (32). Claims that the intracellular structures are too large to be nuclei and that they are preserved in late mineralization phases, after the decay of original biological structures (33, 34), have already been refuted (12, 35). However, the nucleus interpretation has been rejected principally on the basis of plausibility and the expectation that other organelles should also be preserved (36). The algal taphonomy experiments demonstrate that nuclei persist postmortem on a time scale compatible with phosphatization (21), and the absence of chloroplasts is further evidence against an algal interpretation.

Bitter Springs: Organelles or shrunken cytoplasm?. The assumption that nuclei (and by extension other organelles) cannot be preserved in fossils rests in bacterium taphonomy experiments conducted to test claims of eukaryotes in the ~830million year (Ma) Bitter Springs Formation, Australia (15, 37). Intracellular structures in Caryosphaeroides, composed of a pale outer ring surrounding a darker inner spheroid (Fig. 4F), were interpreted as a nucleus (38); diffuse structures around a dark, angular central structure in Glenobotrydion were interpreted as chloroplasts surrounding a pyrenoid (39) or nuclear residues (Fig. 4G) (40). Taphonomy experiments demonstrated that bacterial cells can produce cytoplasmic collapse structures that resemble nuclei, leading to the null interpretation of the Bitter Springs intracellular structures as taphonomic artifacts of bacterial cells (15). However, our complementary experiments using algae show that the organelle interpretations cannot be rejected so easily; the structures in Caryosphaeroides and Glenobotrydion could be nuclei or chloroplasts but are unlikely to be pyrenoids on the basis of the relative decay resistance of these organelles. The intracellular structures in Glenobotrydion resemble decayed remains of a chloroplast surrounding the remnants of a pyrenoid, while more data are needed on the consistency of size, number, shape, and locus of the intracellular structures in Caryosphaeroides to aid their interpretation.

Rafatazmia: The earliest red alga?. Rafatazmia chitrakootensis, from the ~1600-Ma Tirohan Dolomite of India, has been interpreted as a rhodophyte and therefore the oldest crown eukaryote (41). Suspended within comparatively large eukaryote-scale cells, there is sometimes a single large, central, rhomboidal structure or several smaller structures located near the septa between cells, interpreted as pyrenoids and pit plugs, respectively (Fig. 4D) (41). Our experiments indicate that pyrenoids would not be present ordinarily without the surrounding chloroplast. Preservation probability does not always correlate with decay resistance (42). However, the structures in the holotype wholly fill the cell and are not readily rationalizable with a chloroplast, nucleus, or their degraded remains. Furthermore, many of these purported intracellular structures are irregular in shape and size and appear to be mineralized in the same phase as void-filling cement, with the exception of the holotype. There is not sufficient evidence to identify pit plugs within the cells; without pit plugs, there is little support for a rhodophyte affinity, and the oldest definitive crown-group eukaryote is therefore Bangiomorpha, a silicified filamentous fossil from the ~1047-Ma Hunting Formation of Canada (Fig. 4E) (43, 44). Despite being well preserved, placement of Bangiomorpha within Bangiaceae is not due to any subcellular detail but its general simplicity and the arrangement of wedge-shaped cells in multiseriate filaments (43); this is insufficient to justify a Bangiaceae or crown-rhodophyte affinity. There are no organelles obviously preserved in the fossils, reflecting considerable decay leaving only recalcitrant cell walls.

The oldest eukaryotes: Nucleated or not?. Unicellular Dictyosphaera and Shuiyousphaeridium (~1700-Ma Ruyang Group of China) are the oldest widely accepted eukaryotic fossils, often preserved associated with intracellular structures that have been compared to nuclei (Fig. 4, H and I) (13). However, despite their consistency of size, locus, number, and shape, the nucleus interpretation has been rejected on the basis of plausibility and the absence of other organelles; they are instead interpreted as contracted cytoplasmic contents (13). Our experimental results demonstrate that the nucleus interpretation cannot be rejected, as it has been, on taphonomic grounds and that the absence of chloroplasts may simply reflect the fact that Dictyosphaera and Shuiyousphaeridium were not photosynthetic eukaryotes. The miniscule size, low abundance, and need for staining in living cells for observation suggest that mitochondria are unlikely to be identifiable in fossil material that is not amenable to transmission electron microscopy analysis or staining. Leptoteichos golubicii [1880-Ma Gunflint Iron Formation, Canada (45)] is an even older candidate eukaryote with intracellular structures originally interpreted as collapsed cytoplasmic contents (Fig. 4J); the authors were reluctant to accept a nucleus and eukaryote interpretation because of its great geologic age. These structures strongly resemble the putative nuclei in Caryosphaeroides but, similarly, they require detailed characterization of size, locus, number, and shape consistency before a definitive conclusion can be reached.

Growing evidence supports the two-domain tree of life, with Eukarya unusually having two stem lineages that arise from their -proteobacterial and archaeal relatives (46). Although there can be little hope of palaeontological insight into the former before its coalescence with the archaeal lineage, our experiments demonstrate that there is promise that aspects of the process of eukaryogenesis relating to the origin of organelles may be preserved in the fossil record. However, while it may be possible to distinguish eukaryote-grade fossils, for instance with a preserved nucleus, it will remain challenging to rationalize whether these represent stem or crown eukaryotes. Hence, evidence of preserved nuclei in Dictyosphaera and Shuiyousphaeridium provides definitive evidence of their eukaryote-grade organization, supplementing circumstantial evidence of an actin skeleton. They provide the oldest definitive evidence of total-group eukaryotes, but definitive evidence of the divergence of crown eukaryotes must rest with the preservation of secondary organelles, specifically chloroplasts and pyrenoids, that is before evidence for the emergence of fungi and metazoans. At present, this record rests with ~1047-Ma Bangiomorpha (44). However, our experiments provide a basis for pushing back the record of both total group and crown eukaryotes based on the preservation of nuclei, chloroplasts, and pyrenoids, illuminating the time scale and pattern of eukaryogenesis and diversification.

The algae were obtained from Sciento.co.uk and immediately sampled to confirm species identification and provide baseline images of the living algae. The algae were then euthanized in 300 mM BME for a minimum of 24 hours, providing time for the cells to settle to the bottom of the tubes. Excess BME was removed with a pipette, and the algae were rinsed in tap water for the freshwater species and artificial seawater for Rhodochorton. Samples were taken immediately after euthanization. Each species was then divided into 32 1-ml tubes and separated into two experimental groups: the oxic group, with the lid of the tube removed and water topped up to prevent desiccation, and the anoxic group, where the lid remained sealed until sampling. The addition of water to the oxic group may have affected the chemical gradients surrounding the algae, and mechanical damage may have occurred while the water was being added. However, since there was little difference between the rates of decay between the oxic and anoxic groups and no difference in the patterns of decay, these appear to have had negligible effects on the decay of the algae. The tubes were then placed in a dark Scientific Laboratory Supplies Ltd. (SLS) incubator at room temperature (17.5C) to control for effects of different temperatures on the speed of decay and sampled every 2 to 4 days for 6 weeks.

To take samples, a small volume of the algae that had settled to the bottom of the tube was removed using a 1-ml Pasteur pipette and transferred to a microscope slide. Tubes were only sampled once, providing 16 samples across the 6 weeks of the experiment. The tip of a pipette was then dipped in 1% methylene blue and mixed into the algae to enhance the contrast, although this was not necessary for Rhodochorton because of its natural coloring. The samples were examined under an Axioskop 40 light microscope with a Leica DFC295 camera. Images were taken of colonies and individual cells using 10, 20, 40, and 100 lenses and the Leica Application Suite version 4.2.0. Conventional adjustments of color levels, contrast, and brightness were performed on the images using Adobe Photoshop CC 2014 version 2.2.

For each sample, a proportion of random cells (around 100 to 160 cells for Chlorella and V. aureus and around 40 cells for Rhodochorton and P. morum) were scored on the basis of whether the nucleus was visible; whether the chloroplast had holes and/or had collapsed; and, in the species with pyrenoids, whether the pyrenoid was visible within the starch grain ring. The numbers of cells counted were based on the abundance of the cells in the images taken during sampling; because of the large size of the colonies of V. aureus and the small size and abundance of cells of Chlorella, more cells were visible in each photograph. Rhodochorton cells are much larger and were therefore less abundant in the photographs, and P. morum colonies are both limited in cell number and overlapping, resulting in fewer visible cells. The data on decay characteristics were analyzed using Microsoft Excel.

E. Javaux, Early eukaryotes in Precambrian oceans, in Origins and Evolution of Life: An Astrobiological Perspective, P. Lpez-Garca, H. Martin, Eds. (Cambridge Astrobiology, Cambridge Univ. Press, 2011), pp. 414449.

R. E. Lee, Phycology (Cambridge Univ. Press, 2008).

Read more:
Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances

Read More...

Genetic Testing: MedlinePlus

January 29th, 2021 2:54 am

What is genetic testing?

Genetic testing is a type of medical test that looks for changes in your DNA. DNA is short for deoxyribonucleic acid. It contains the genetic instructions in all living things. Genetic tests analyze your cells or tissue to look for any changes in

Genetic testing may be done for many different reasons, including to

Genetic tests are often done on a blood or cheek swab sample. But they may also be done on samples of hair, saliva, skin, amniotic fluid (the fluid that surrounds a fetus during pregnancy), or other tissue. The sample is sent to a laboratory. There, a lab technician will use one of several different techniques to look for genetic changes.

The benefits of genetic testing include

The physical risks of the different types of genetic testing are small. But there can be emotional, social, or financial drawbacks:

The decision about whether to have genetic testing is complex. In addition to discussing the test with your health care provider, you can meet with a genetic counselor. Genetic counselors have specialized degrees and experience in genetics and counseling. They can help you understand the tests and weigh the risks and benefits. If you do get a test, they can explain the results and make sure that you have the support that you need.

Continued here:
Genetic Testing: MedlinePlus

Read More...

21 Common Genetic Disorders: Types, Symptoms, Causes …

January 29th, 2021 2:54 am

What is a genetic disease?

A genetic disease is any disease caused by an abnormality in the genetic makeup of an individual. The genetic abnormality can range from minuscule to major -- from a discrete mutation in a single base in the DNA of a single gene to a gross chromosomal abnormality involving the addition or subtraction of an entire chromosome or set of chromosomes. Some people inherit genetic disorders from the parents, while acquired changes or mutations in a preexisting gene or group of genes cause other genetic diseases. Genetic mutations can occur either randomly or due to some environmental exposure.

What are the four types of genetic disorders (inherited)?

There are a number of different types of genetic disorders (inherited) and include:

The baby with Down syndrome has a hallmark appearance. However, every aspect of the appearance does not need to be present as the phenotype, the way the genes make the child look, can be markedly different for each patient. Common Down syndrome symptoms are:

7 single gene inheritance disorders

Single gene inheritance is also called Mendelian or monogenetic inheritance. Changes or mutations that occur in the DNA sequence of a single gene cause this type of inheritance. There are thousands of known single-gene disorders. These disorders are known as monogenetic disorders (disorders of a single gene).

Single-gene disorders have different patterns of genetic inheritance, including

Some examples of single-gene disorders include

7 common multifactorial genetic inheritance disorders

Multifactorial inheritance is also called complex or polygenic inheritance. Multifactorial inheritance disorders are caused by a combination of environmental factors and mutations in multiple genes. For example, different genes that influence breast cancer susceptibility have been found on chromosomes 6, 11, 13, 14, 15, 17, and 22. Some common chronic diseases are multifactorial disorders.

Examples of multifactorial inheritance include

Multifactorial inheritance also is associated with heritable traits such as fingerprint patterns, height, eye color, and skin color.

4 chromosomal abnormalities

Chromosomes, distinct structures made up of DNA and protein, are located in the nucleus of each cell. Because chromosomes are the carriers of the genetic material, abnormalities in chromosome number or structure can result in disease. Chromosomal abnormalities typically occur due to a problem with cell division.

For example, Down syndrome (sometimes referred to as "Down's syndrome") or trisomy 21 is a common genetic disorder that occurs when a person has three copies of chromosome 21. There are many other chromosomal abnormalities including:

Diseases may also occur because of chromosomal translocation in which portions of two chromosomes are exchanged.

3 mitochondrial genetic inheritance disorders

This type of genetic disorder is caused by mutations in the non-nuclear DNA of mitochondria. Mitochondria are small round or rod-like organelles that are involved in cellular respiration and found in the cytoplasm of plant and animal cells. Each mitochondrion may contain 5 to 10 circular pieces of DNA. Since egg cells, but not sperm cells, keep their mitochondria during fertilization, mitochondrial DNA is always inherited from the female parent.

Examples of mitochondrial disease include

What is the human genome?

The human genome is the entire "treasury of human inheritance." The sequence of the human genome obtained by the Human Genome Project, completed in April 2003, provides the first holistic view of our genetic heritage. The 46 human chromosomes (22 pairs of autosomal chromosomes and 2 sex chromosomes) between them house almost 3 billion base pairs of DNA that contains about 20,500 protein-coding genes. The coding regions make up less than 5% of the genome (the function of all the remaining DNA is not clear) and some chromosomes have a higher density of genes than others.

Most genetic diseases are the direct result of a mutation in one gene. However, one of the most difficult problems ahead is to further elucidate how genes contribute to diseases that have a complex pattern of inheritance, such as in the cases of diabetes, asthma, cancer, and mental illness. In all these cases, no one gene has the yes/no power to say whether a person will develop the disease or not. It is likely that more than one mutation is required before the disease is manifest, and a number of genes may each make a subtle contribution to a person's susceptibility to a disease; genes may also affect how a person reacts to environmental factors.

Medically Reviewed on 10/17/2019

References

United States. National Heart, Lung, and Blood Institute. "Cystic Fibrosis." <https://www.nhlbi.nih.gov/health-topics/cystic-fibrosis>.

United States. National Human Genome Research Institute. "Frequently Asked Questions About Genetic Disorders." <https://www.genome.gov/19016930/faq-about-genetic-disorders/>.

Follow this link:
21 Common Genetic Disorders: Types, Symptoms, Causes ...

Read More...

Genetic Counseling Online Course – School of Medicine …

January 29th, 2021 2:54 am

Taught by the genetic counselor faculty of the University of South Carolina Genetic Counseling Program, this specially designed genetic counseling online course,Genetic Counseling: Career for the Future, is comprised of lectures from genetic counselors, readings from professional literature and practical activities to help broaden your understanding of the profession and prepare for graduate school.

Online course topics include genetic counseling as a health care profession,with an introduction to various arenas of genetic counseling including prenatal, pediatric, cancer and adult. You'll explore clinical, laboratory and research roles, the counselor-patient relationship, ethical issues and other hot topics, as well as strategies for preparing for graduate education.

Summer 2020 Session:June 8 - August 28Registration Deadline isJune 3

Fall 2020 Session:August 17 November 13Registration Deadline is August 12

Spring 2021 Session:January 11 April 2Registration Deadline is January6

Register Now!

Ourgenetic counseling online course is offered over a 12-week period with two to three hours of self-paced activity per week. Upon completion, youll receive a continuing education certificate to add to your resume. There are no prerequisites for the course. Designed as an in-depth exploration of genetic counseling, the course will demonstrate your commitment to genetic counselor education at the same time you become savvy about the profession and considerations for graduate school.

The Genetic Counseling Program strives to increase diversity among genetic counselors and promotes an inclusive learning environment. As part of our Diversity Recruitment Initiative, a limited number of discounted registration fees will be granted to individuals of underrepresented communities of color. Come learn with us!

One of my reasons for taking this course was to feel inspired every week and gain further insight into the field of genetic counseling as I prepare for applications, and that is definitely happening! I really appreciate the range of assignments and I think it's a good combination to help structure our learning.

The work load is just right. Everything we have done has made me more and more excited about working towards my career as a genetic counselor.

I can tell that you have put a lot of time and effort into making this course as informative, up-to-date, and engaging as an in-person class.

It's fun to communicate with so many people with different backgrounds. Everyone shares their different experiences and I am constantly learning.

I've enjoyed reading the articles and responding to others on the discussion board. The videos have been so insightful --hearing from genetic counselors, learning about their jobs, and what excites them has been very meaningful to me.

With all of the information being online, I can start and stop the work as I please and always find time to do the readings and activities for the week. I really enjoy that the fact that the information comes from such a variety of resources...especially resources that I would have never known about otherwise. All of the articles, websites and videos have been so informative and learning more information about the field has deepened my passion for genetic counseling!"

You may also be interested in theSummer Internship.

See the rest here:
Genetic Counseling Online Course - School of Medicine ...

Read More...

4 New Life Sciences Licensing Deals and Investments to Watch – BioSpace

January 29th, 2021 2:54 am

Today marked some wheeling and dealing in the life sciences industry as several companies licensed products or invested in other companies. Heres a look.

Eli Lillyand Asahi Kasei Pharma Eli Lilly and Company inked a license agreement with Tokyos Asahi Kasei Pharma Corporation. In it, Lilly picks up exclusive rights to AK1780 from Asahi. The drug is an oral P2X7 receptor antagonist that recently finished a Phase I dosing study. P2X7 receptors are associated with neuroinflammation that drives chronic pain conditions.

Under the terms of the deal, Lilly will handle future global development and regulatory activities. Lilly is paying Asahi Kasei Pharma $20 million up front and the Japanese company is eligible for up to $210 million in development and regulatory milestones. Asahi Kasei will retain the rights to promote the drug in Japan and China, including Hong Kong and Macau. If it makes it to market, Asahi Kesei will also be eligible for up to $180 million in sales milestones and tiered royalties from the mid-single to low-double digits.

Lilly is committed to developing novel medicines that may provide relief for patients suffering with various pain conditions, said Mark Mintun, vice president of pain and neurodegeneration research at Lilly. We are pleased to license this molecule from Asahi Kasei Pharma, and look forward to developing it further as a potential treatment for neuroinflammatory pain conditions.

Artiva Biotherapeutics and Merck San Diego-based Artiva Biotherapeutics announced an exclusive global collaboration and license agreement with Merck to develop novel chimeric antigen receptor (CAR)-NK cell therapies against solid tumor-associated antigens. They will leverage Artivas off-the-shelf allogeneic NK cell manufacturing platform and its proprietary CAR-NK technology. At first, the collaboration will include two CAR-NK programs with an option for a third. None of them are currently part of Artivas current or planned pipeline. Artiva will develop the programs through the first GMP manufacturing campaign and to preparation for the Investigational New Drug (IND) application, where Merck will take over clinical and commercial development.

Merck is paying Artiva $30 million upfront for the first two programs and another $15 million if Merck chooses to go ahead with the third. Artiva will be up for development and commercial milestones up to $612 million per program and royalties on global sales. Merck also is ponying up research funding for each program.

Our NK platform has been developed to be truly off-the-shelf and we believe it will be further validated by this exclusive collaboration with Merck, as we work together to bring cell therapies to all patients who may benefit, said Peter Flynn, chief operating officer of Artiva.

NeuBase Therapeutics and Vera Therapeutics Pittsburgh-based NeuBase Therapeutics announced a binding agreement to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera Therapeutics, formerly called TruCode Gene Repair. Vera is based in South San Francisco. On January 19, Vera announced its launch with a $80 million Series C financing led by Abingworth LLP and joined by Sofinnova Investments, Longitude Capital, Fidelity Management & Research Company, Surveyor Capital, Octagon Capital, Kliner Perkins, GV and Alexandria Venture Investments. Veras lead clinical candidate is atacicept, a novel B cell and plasma cell inhibitor being developed for patients with IgA nephropathy (IgAN).

The technology acquired by NeuBase has shown the ability to resolve disease in genetic models of several disease indications. NeuBase is focused on genetic medicine.

With this acquisition, we enhance our PATrOL platform, furthering our unique ability to directly engage and correct malfunctioning genes with exquisite precision to address the root causes of a wide variety of human diseases, said Dietrich A. Stephan, chief executive officer of NeuBase. These assets extend and refine our PATrOL platforms capabilities and accelerates, through our Company, to bring the rapidly growing genetic medicines industry toward a single high-impact focal point. We are committed to advancing our pipeline and candidates to the clinic and to exploiting the full potential of PNA technology to continue creating value for our shareholders and importantly, for patients.

Bio-Techne Corporation and Changzhou Eminence Biotechnology Co Minneapolis-based Bio-Techne Corporation announced an initial minority strategic equity investment in Chinas Changzhou Eminence Biotechnology Co. Eminence plans to use the financing to expand its manufacturing capacity and increase the service capabilities of its China-based GMP media production facility. Eminence, based in Changzhou City, Jiangsu, China, launched in 2016 and initially focused on manufacturing and selling best-in-class media to life science companies, including Chinese Hamster Ovary (CHO) cells and other serum-free media products and services. The company is currently finishing and scaling its GMP production facility, which it plans to complete by the end of this year.

With our protein analysis instruments and expanding GMP protein capabilities, Bio-Techne continues to expand its offering of products and tools critical for bioprocessing, said Chuck Kumeth, president and chief executive officer of Bio-Techne. Investing in Eminence not only gives Bio-Techne a foothold in providing additional products and services to support the critical needs of the rapidly growing Chinese biopharmaceutical industry, but also fits extremely well with our existing high-growth product portfolio in China. We look forward to working with the Eminence team.

Most Read Today

Continued here:
4 New Life Sciences Licensing Deals and Investments to Watch - BioSpace

Read More...

Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer – PRNewswire

January 29th, 2021 2:54 am

Dr. Li has over 30 years of experience in basic and applied biomedical research. She joins Neurophth from the University of Louisville School of Medicine, where she was a professor in the department of Ophthalmology and Visual Sciences for over 14 years. Her research focuses on the role of Hippo/YAP1 signaling pathway on different stages of ocular development, NF-kB/IKK2 inhibition of neovascularization, and gene discovery screening for eye diseases using mouse models.

Throughout her career, Dr. Li has contributed to more than 45 publications in journals including Investigative Ophthalmology & Visual Science (IOVS), Proceedings of the National Academy of Sciences of the United States of America(PNAS), Nature Review Immunology, and Science. She is currently the editorial board member of Scientific Reportsand Source Journal of Ophthalmology. Dr. Li holds a Ph.D. in cell biology from the Washington University in St. Louis and obtained both her Bachelor's and Master of Science degrees in Genetics from Beijing University.

"We are thrilled to have Dr. Li on our team, bringing over 3 decades of her diverse experience in basic and applied biomedical research," said Bin Li, M.D., Ph.D., Founder and Chairman of the Board of Neurophth. "Given her prior experience at Baylor College of Medicine mentored by Dr. Savio Woo, an internationally recognized expert in molecular human genetics and gene therapy, and Dr. Mark Kay, a leading researcher in the fields of AAV gene therapy and the current Head of Division of Human Gene Therapy at the Stanford University School of Medicine, Dr. Li has extensive knowledge in gene therapy for hepatic deficiencies, ocular diseases, and viral vector reconstruction."

"We are excited to have Qiutang join and expand our exceptional research and development team. She brings a wealth of experience in gene therapies for ocular diseases to Neurophth," said Alvin Luk, Ph.D., M.B.A., C.C.R.A., Chief Executive Officer at Neurophth. "Her deep understanding of viral vector design and animal models in the inhibition of neovascularization for ocular diseases, such as age-related macular degeneration and diabetic retinopathy, further bolsters our ability to deliver on our growing pipeline of clinical programs and platform capabilities."

"It has been captivating to watch the scale, scope, and speed with which Neurophth has successfully transformed itself into an innovative and diversified gene therapy company," said Dr. Li. "I look forward to being a part of Neurophth team as the company executes the next stage of its growth strategy and expands its pipeline of gene therapy candidates focused on ocular and non-ocular diseases, building a brighter future for patients worldwide."

About Neurophth

Neurophth is China's first gene therapy company in ophthalmic diseases.Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and the U.S., Neurophth, a fully integrated company, is striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. Our AAV validated platform which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, successfully delivered proof-of-concept data with investigational gene therapies in the retina. Our most advanced investigational candidate, NR082 (rAAV2-ND4), in development for the treatment ofND4-mutated LHON, has received orphan drug designations in theU.S. The pipeline also includesND1-mutated LHON, autosomal dominant optic atrophy, glaucoma, wAMD/DME, and other preclinical candidates. Neurophth has initiated the scaling up in-house process in single-use manufacturing technologies to support future commercial demand at the Suzhou facility. To learn more about us and our growing pipeline, visitwww.neurophth.com.

SOURCE Neurophth Therapeutics, Inc.

http://www.neurophth.com

Read the original here:
Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer - PRNewswire

Read More...

Are Gene Therapies the Medicine of the Future? – BioSpace

January 29th, 2021 2:54 am

Over the next 10 years, gene therapies are expected come into their own as a treatment option for a variety of diseases. So far, two such therapies have snagged regulatory approval, Novartis Zolgensma for spinal muscular atrophy, and Sparks Luxturna for a rare form of genetic blindness. More are waiting their turn.

Multiple companies are delving into gene therapy research with hopes of developing a one-time treatment for devastating genetic diseases. Gene therapies offer great reward in the form of treating various devastating diseases, but there are also significant risks. Over the past year, several clinical studies have been halted or scrapped due to safety concerns.

Bay Area-based Audentes Therapeutics had a temporary hold placed on the gene therapy under development for X-linked myotubular myopathy following reports of several patient deaths. That hold has since been lifted by the U.S. Food and Drug Administration. Uniqure also saw a hold placed on its hemophilia B trial after a patient in the study developed liver cancer. The hold was placed weeks after the company announced promising Phase III results at a conference in December.

Despite those risks, hundreds of millions of dollars in research dollars are being invested in gene therapies because of the potential near-curative capabilities the technology could offer. In December, life sciences giant Bayer launched a cell and gene therapy platform within its pharmaceutical division in order to become a leading company within a rapidly emerging and evolving field that offers the potential of life-saving therapies. Eli Lilly also dove into the field in December with the acquisition of Prevail Therapeutics. That deal was expected to extend Eli Lillys research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets.

This week, German scientists reported they were able to use gene therapy to help paralyzed mice run again. The researchers were able to genetically engineer a unique protein dubbed hyper-interleukin-6, which was then able to stimulate the regeneration of nerve cells in the visual system. A few weeks after the treatment, the injured animals were able to walk again.

Scientists in China announced the development of a gene therapy that could potentially reverse the effects of ageing. Initial research was conducted with mice, but if it is proven to be safe, human testing could begin. As Reuters reported, the method involved inactivating a gene called kat7 which the scientists found to be a key contributor to cellular ageing. Researchers used CRISPR/Cas9 to screen thousands of genes for those which were particularly strong drivers of cellular senescence, the term used to describe cellular ageing, Reuters said.

Earlier this month, a public-private partnership in Boston formed to open a new facility to boost advances in cell and gene therapies. This creation of this new facility is being helmed by Harvard University and the Massachusetts Institute of Technology. Those prestigious universities are partnering with industry members such as Fujifilm Diosynth Biotechnologies, Cytivia and Alexandria Real Estate Equities, as well as multiple research hospitals. Part of the goal of this new institute, which is still unnamed at this point, is to boost the supply of materials for research and early clinical studies, provide space for some research and also offer training in equipment used for gene therapies, The Harvard Gazette reported this week.

On Monday, Curadigm, a subsidiary of France-based Nanobiotix, forged a collaboration with Sanofi to assess if that companys Nanoprimer technology is a promising option to significantly improve gene therapy development. The goal of the project is to establish proof-of-concept for the Nanoprimer as a combination product that could improve treatment outcomes for gene therapy product candidates.

Many promising nucleic acid-based therapeutics administered intravenously are limited in their efficacy due to rapid clearance in the liver, which prevents these therapies from reaching the necessary accumulation in target tissues to generate their intended outcomes. Additionally, accumulation in the liver, rather than in the target tissues, can lead to dose-limiting hepatic toxicity, Nanobiotix said in its announcement. The Nanoprimer is designed to precisely and temporarily occupy therapeutic clearance pathways in the liver. Delivered intravenously, immediately prior to the recommended therapy, the technology acts to prevent rapid clearancethereby increasing bioavailability and subsequent accumulation of therapeutics in the targeted tissues.

The Nanoprimer is a combination product candidate that does not alter or modify the therapies it is paired with, which means if the research with Sanofi is successful, Curadigm could seek out other opportunities for its technology.

Most Read Today

More:
Are Gene Therapies the Medicine of the Future? - BioSpace

Read More...

Two Gene Therapies Fix Fault in Sickle Cell Disease and -thalassemia – MD Magazine

January 29th, 2021 2:53 am

Two different gene therapies have been used to mitigate a mechanism underlying development of sickle cell disease (SCD) and transfusion-dependent -thalassemia (TDT), and both have demonstrated clinical success in separate, concurrently published trials.

The hemoglobinopathies manifest after fetal hemoglobin synthesis is replaced by adult hemoglobin in individuals who have inherited a mutation in the hemoglobin subunit gene (HBB).Identifying factors in the conversion from fetal to adult hemoglobin synthesis, however, has provided potential targets for therapeutic intervention.

Gene therapy that can safely arrest or reduce the conversion offers the potential for a one-time treatment to obviate the need for lifetime transfusions and iron chelation for patients with TDT, and the pain management, transfusions and hydroxyurea administration for those with SCD.

Two groups of investigators have now reported in The New England Journal of Medicine that, using different gene therapy techniques that target the transcription factor, BCL11a, involved in the globin switching, they have improved clinical outcomes in patients with TDT and with SCD.

In an editorial in the issue featuring the 2 studies, Mark Walters, MD, Blood and Marrow Transplant Program, University of California, San Francisco-Benioff Children's Hospital, welcomed the breakthroughs.

"These trials herald a new generation of broadly applicable curative treatments for hemoglobinopathies," Walters wrote.

In one clinical trial with 2 patients, one with TDT and the other with SCD, Haydar Frangoul, MD, MS, Medical Director, Pediatric Hematology/Oncology, Sarah Cannon Center for Blood Cancer at the Children's Hospital at Tristar Centennial, and colleagues administered CRISPR-Cas9 gene edited hematopoietic stem and progenitor cells (HSPCs) with reduced BCL11A expression in the erythroid lineage.

The product, CTX001, had been shown in preclinical study to restore -globulin synthesis and reactivate production of fetal hemoglobin. Both patients underwent busulfan-induced myeloablation prior to receiving the treatment.

The investigators suggested that the CRISPR-Cas9-based gene-edited product could change the paradigm for patients with these conditions, if it was found to successfully and durably graft, produce no "off-target" editing products, and, importantly, improve clinical course.

"Recently approved therapies, including luspatercept and crizanlizumab, have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addressed the underlying cause of the disease nor fully ameliorates disease manifestations," Frangoul and colleagues wrote.

The investigators reported that both patients had "early, substantial, and sustained increases" in pancellularly distributed fetal hemoglobin levels during the 12-month study period. Further, the patients no longer required transfusions, and the patient with SCD no longer experienced vaso-occlusive episodes after the treatment.

In commentary accompanying the report, Harry Malech, MD, Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH), Bethesda, MD, described the investigators' application of the gene-editing technology as a "remarkable level of functional correction of the disease phenotype."

"With tangible results for their patients, Frangoul et al have provided a proof of principle of the emerging clinical potential for gene-editing treatments to ameliorate the burden of human disease," Malech pronounced.

In the other published trial, with 6 patients with SCD, Erica Esrick MD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, and colleagues described results with infusion of gene-modified cells derived from lentivirus insertion of a gene that knocks down BCL11a by encoding an erythroid-specific, inhibitory short-hairpin RNA (shRNA).

The severity of SCD that qualified patients for enrollment included history of stroke (n = 3), frequent vaso-occlusive events (n = 2) and frequent episodes of priapism (1).Patients were followed for 2 years, and offered enrollment in a 13-year long-term follow-up study.The infusion of the experimental drug BCH-BB694, from the short hairpin RNA embedded within an endogeonous micro RNA scaffold (termed a shmiR vector), was initiated after myeloablation with busulfan.

Esrick and colleagues reported that, at median follow-up of 18 months (range, 7-29), all patients had engraftment and a robust and stable HbF induction broadly distributed in red cells.Clinical manifestations of SCD were reduced or absent during the follow-up period; with no patient having a vaso-occlusive crisis, acute chest syndrome, or stoke subsequent to the gene therapy infusion.Adverse events were consistent with effects of the preparative chemotherapy.

"The field of autologous gene therapies for hemoglobinopathies is advancing rapidly," Esrick and colleagues reported, "including lentiviral trials of gene addition in which the nonsickling hemoglobin is formed from an exogenous -globin or modified -globin gene."

Walters agreed that gene therapy is rapidly progressing, but expressed concern about the large gap that looms between laboratory bench and clinical bedside, particularly for this affected population.

"Access to and delivery of these highly technical therapies in patients with sickle cell disease will be challenging and probably limited to resource-rich nations, at least in the short term," Walters commented.

The studies, CRISPR-Cas9 Gene Editing for Sickle Cell Disease and -Thalassemia, as well as, Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease, were published online in The New England Journal of Medicine.

Read the rest here:
Two Gene Therapies Fix Fault in Sickle Cell Disease and -thalassemia - MD Magazine

Read More...

Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing – Labiotech.eu

January 29th, 2021 2:53 am

With the rising demand for cell and gene therapies, the need for manufacturing innovation has never been higher. A surge of deals and expansions in the last year is fuelling the push to truly make these therapies widely available and affordable.

Cell and gene therapies offer huge potential to treat a wide range of diseases including cancer, neurological, and genetic diseases. They have even shown promise to treat the symptoms of Covid-19.

The amount of academic and early-stage biotech research in this area has skyrocketed over the last few years. According to the Alliance for Regenerative Medicine, there are currently 1,220 ongoing clinical trials in this space, 152 of which are at phase III. Despite the global pandemic, investment in this area is also at a record high around the world, with the equivalent of 15.7B invested in 2020, a figure double that of 2019.

But research alone cannot get these complex treatments to patients. The sharp discrepancy between the high number of products in early-stage development and the still very small number that have made it onto the market, as well as their cost, speaks to the impact and importance of cost-effective and scalable manufacturing, Ryan Cawood, CEO of Oxgene (previously Oxford Genetics), told me. Oxgene is a UK biotech aiming to improve manufacturing for cell and gene therapies.

To meet this challenge, cell and gene therapy producers are exploding into motion. With 2021 only just getting started, weve seen manufacturing deals between Vigeneron and Daiichi Sankyo, Sirion Biotech and Cellectis, and Cevec and Biogen. The giant Thermo Fisher Scientific absorbed the Belgian viral vector producer Henogen for 724M. And CDMO heavyweights like Cognate BioServices and Polyplus Transfection have announced expansions to their manufacturing capacity.

Thedifficulties with manufacturing the recently approved Covid-19 mRNA vaccines in high enough quantities has really highlighted the importance of having a solid manufacturing strategy in place. This lesson applies equally to companies trying to take cell and gene therapies to market.

Stuck in the first generation

Despite the huge increase in development of cell and gene therapies over the past couple of years, manufacturing technology for these therapies is largely still at the first-generation stage. This can make scaling up a challenge.

Often cell and gene therapy manufacturing processes are highly manual stemming from the early academic or process development stage and, without adequate technology solutions available currently, these processes often remain this way through clinical trials and then into commercial manufacturing, said Jason Foster, CEO of Ori Biotech, a London- and New Jersey-based company focusing on cell and gene therapy manufacturing.

These first-generation processes cause manufacturing to be expensive, highly variable and low-throughput, which reduces the ability of patients to access these potentially life-saving therapies.

Another problem common to all bio-based therapeutics is that any product sourced from a live cell or a component of one is subject to a lot more variation than a simpler pharmaceutical product.

Most gene therapies are built on viruses found in nature. They have not evolved for very high productivity in a large-scale, animal component-free bioreactor, said Cawood.

The more complicated the biologic becomes, the more parts of it require optimization, and the more analytics you require.

According to Kevin Alessandri, the cofounder and CEO/CTO of the French company TreeFrog Therapeutics, there is also a lot of waste in cell therapy manufacturing.

Yields are impaired by high cell death at every passage, and genetic alterations inevitably arise, said Alessandri. When it comes to producing commercial batches to treat thousands of patients, scaling out 2D cell culture processes is far too expensive and poses batch-to-batch reproducibility issues.

While many in the industry are now turning to bioreactors to produce cells on a bigger scale, this is also not without problems. Impeller-induced shear stress is damaging the cells, thus negatively impacting cell viability and triggering undesired genetic mutations, explained Alessandri.

Taking manufacturing up a gear

What are companies in this space doing to make scaling up cell and gene therapies easier, quicker, and cheaper?

Ori Biotech raised24.8M in Series A funding in October last year to develop an automated and robotic manufacturing system to minimize the number of manual steps needed to produce a given cell or gene therapy. This speeds up the process as well as making it more accurate. Another advantage of the technology is that it can tailor the production capacity according to demand.

This is impossible to do in most current processes, which involve manual tube welding and transfers from flask to bag to bigger bag to bioreactor, said Foster, adding that this increases cost and variability while constraining throughput. Oris technology, in contrast, could take years off the production timeline and cut costs by as much as 80%.

London-based Synthace is one of several companies trying to improve advanced therapeutic manufacturing by developing software and computer systems to optimize the process, rather than industrial machinery.

Peter Crane, Corporate Strategy Manager for the company, said that in-depth data analysis and planning before starting the manufacturing process can make a big difference to outcomes, and that connected software can help make this task easier.

The best way to remove some of the risk associated with biomanufacturing of these products is to solve as many problems as possible before manufacturing.

In addition to making the process quicker, cheaper, and more accurate, computing tools can also help with quality control and tracking. In cell therapy manufacturing, especially autologous products, line of sight around electronic batch records, as well as the vein-to-vein supply chain, is incredibly important, emphasized Crane.

Another company specifically focusing on logistics and quality control is the Cardiff- and San Francisco-based TrakCel, which nailed deals with Ori Biotech in February and the UKs National Health Service in November.

The company TreeFrog Therapeutics works with cell encapsulation technology to improve quality and reduce waste, albeit from a more mechanical viewpoint. The company launched an industrial demonstration plant in June last year, followed by two co-development deals with undisclosed big pharma partners.

Encapsulated stem cells spontaneously self-organize in an in vivo-like 3D conformation promoting fast and homogeneous growth, as well as genomic stability, said Alessandri. The resulting 3D stem cell colony can then be differentiated in the capsule into functional microtissues ready for transplantation.

With our technology, which is based on high-throughput microfluidics capable of generating over 1,000 capsules per second, it becomes possible to expand and differentiate stem cells at a large scale, in industrial bioreactors, with best-in-class cell quality and reduced operating costs.

Oxgene has a focus on scaling up production for manufacturers. In September, the company launched a technology to scale up manufacturing of viral vector production with less contamination and a 40-fold improvement in yield compared to current methods. Oxgenes expertise with viral vectors also prompted a collaboration deal in April with the CDMO Fujifilm Diosynth Biotechnologies.

Innovation in new manufacturing technologies just hasnt kept pace with the level of discovery around genetic disease and potential avenues open to treat them, or even development of the viral vectors themselves, said Cawood. This is definitely changing though.

Enter the second generation of manufacturing

Cell and gene therapy manufacturing is definitely hot right now, boosted by increased needs from biotech and pharma companies developing Covid-19 vaccines and therapies, and by notable increases in investment.

Huge advances in gene and cell therapies over the last few years, such as the approval of the eye gene therapy Luxturna and the first CAR T-cell therapies, mean the demand for new manufacturing technologies has also increased exponentially.

A lot of very promising programs are now in the pipeline, and patients are waiting for their approval, said Alessandri. Industry urgently needs robust manufacturing technology, capable of serving millions of patients.

European biotechs are busy developing second-generation technologies to allow easier and cheaper scale up, producing higher quality products with less waste. They could start to phase out first-generation methods very soon.

The realm of cell manufacturing in industrial and food biotech is also likely to see big breakthroughs in the coming years. Earlier this month, for instance, the nutrition and health giant Royal DSM set up a lab in the Netherlands dedicated to applying artificial intelligence (AI) to the challenge of growing microbial strains at a commercial scale.

Rapid improvements in advanced computing options such as AI and machine learning technology, as well as robotics, are already having an effect on the industry, but this will only get bigger as time goes on.

Cover image from Elena Resko. Body text image from Shutterstock

Follow this link:
Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing - Labiotech.eu

Read More...

Page 264«..1020..263264265266..270280..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick